Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults

IF 2.1 4区 医学 Q3 VIROLOGY
A. Igarashi, K. Togo, Yasuhiro Kobayashi, Kazumasa Kamei, N. Yonemoto, N. Ishiwada
{"title":"Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults","authors":"A. Igarashi, K. Togo, Yasuhiro Kobayashi, Kazumasa Kamei, N. Yonemoto, N. Ishiwada","doi":"10.2217/fvl-2023-0069","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDV-infant (n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged <1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and OAs.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fvl-2023-0069","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDV-infant (n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged <1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and OAs.
日本婴儿和老年人与呼吸道合胞病毒相关的住院和门诊费用
目的:评价日本呼吸道合胞病毒(RSV)医疗资源的使用情况。方法:使用JMDC和医学数据视觉(MDV)索赔数据库,我们回顾性评估了呼吸道合胞病毒诊断的婴儿(<12个月)和老年人(OAs,≥60岁)队列的住院/重症监护费用和住院时间。我们分析了帕利单抗在婴儿中的使用情况和成本。结果:住院患者的平均费用为2823美元$2851;以及6609美元(131日元/$)的JMDC婴儿(n=13752);MDV婴儿(n=22142);和MDV-OA队列(n=165)。年龄<1个月、有危险因素和严重呼吸道合胞病毒疾病的患者的平均费用更高。JMDC婴儿队列中帕利单抗预防的平均累计成本为6796美元/年。结论:呼吸道合胞病毒对婴儿和高龄产妇造成巨大的经济负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Future Virology
Future Virology 医学-病毒学
CiteScore
4.00
自引率
3.20%
发文量
84
审稿时长
6-12 weeks
期刊介绍: Future Virology is a peer-reviewed journal that delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this ever-expanding area of research. It is an interdisciplinary forum for all scientists working in the field today.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信